KAM: Effect of Nutritional Ketosis on Alcohol Metabolism

Sponsor
University of Pennsylvania (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06065657
Collaborator
(none)
20
1
4
38
0.5

Study Details

Study Description

Brief Summary

The research study is being conducted in health controls to better understand the effects of ketosis on brain functioning after 3 different, randomly assigned, 3-day dietary interventions and the acute effects of alcohol after consuming about 4-5 alcohol beverages. The labs visits will use magnetic resonance imaging (MRI) scans to study the brain, measuring levels of nicotinamide adenine dinucleotide (NAD), lactate, neurotransmitters glutamate, and Gamma-aminobutyric acid (GABA).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Ketone Supplement
  • Other: Control Diet
  • Other: Ketogenic diet
  • Drug: Ethanol
N/A

Detailed Description

The research study is being conducted to better understand the effects of ketosis on brain functioning and the acute effects of alcohol. Healthy participants will undergo three randomly assigned dietary interventions, each lasting three days, followed by a study lab visit day on day 4. The three interventions are: (1) Eat a ketogenic diet for 3 days, (2) eat a control diet for 3 days with a ketone supplement drink, and (3) eat a control diet for 3 days. The dietary interventions will be spaced 1 week apart. The ketone supplement drink (Kenetik, Vitanav inc, Washington DC) is a dietary supplement that has been extensively studied in humans and is designated by the FDA as Generally Recognized as Safe (GRAS). Its use in this study is experimental. On the day of the 3 labs visits days, magnetic resonance imaging (MRI) will be used to study the brain. Specifically, levels of nicotinamide adenine dinucleotide (NAD) (a coenzyme that is important for energy metabolism), lactate (a metabolite produced during energy metabolism), and neurotransmitters glutamate and GABA. Following the scans, participants will be provided a dose of alcohol that will elevate participants breath alcohol levels to approximately 0.08% to measure the acute effects of alcohol.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Three-way, open-labeled, crossover trial in which participants will undergo three alcohol tolerance tests, each following a 3-days dietary intervention: (1) control diet (~ 50% kcal carbohydrates), (2) ketogenic diet (~5-10% kcal carbohydrates), and (3) control diet with 3x daily administration of 10 g Ketone Supplement (KS) drink (30 g/day, Kenetik: ketone Drink, VitaNav Inc., Washington D.C.).Three-way, open-labeled, crossover trial in which participants will undergo three alcohol tolerance tests, each following a 3-days dietary intervention: (1) control diet (~ 50% kcal carbohydrates), (2) ketogenic diet (~5-10% kcal carbohydrates), and (3) control diet with 3x daily administration of 10 g Ketone Supplement (KS) drink (30 g/day, Kenetik: ketone Drink, VitaNav Inc., Washington D.C.).
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effect of Nutritional Ketosis on Alcohol Metabolism
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2025
Anticipated Study Completion Date :
Dec 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ketogenic diet

Eat a ketogenic diet for 3 days

Drug: Ethanol
After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
Other Names:
  • Alcohol
  • Placebo Comparator: Control Diet

    Eat a control diet for 3 days

    Drug: Ethanol
    After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
    Other Names:
  • Alcohol
  • Experimental: Ketone supplement

    Eat a control diet for 3 days with a ketone supplement drink

    Other: Control Diet
    Control Diet breakfast, lunch, and dinner for 3 days.
    Other Names:
  • ~ 50% kcal carbohydrates diet
  • Drug: Ethanol
    After 3 days of diet intervention, participants will receive alcohol drinks that dose-adjusts for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%
    Other Names:
  • Alcohol
  • Experimental: Alcohol Intervention

    Alcohol lab, participants will receive ethanol drinks that are dose-adjusted for body weight and sex differences in pharmacokinetics and calculated to obtain a final breath alcohol concentration of 0.08%

    Dietary Supplement: Ketone Supplement
    Ketone supplement 3x day with control diet for 3 days.
    Other Names:
  • D-Beta-hydroxybutyric acid and R-1,3 butanediol
  • Other: Control Diet
    Control Diet breakfast, lunch, and dinner for 3 days.
    Other Names:
  • ~ 50% kcal carbohydrates diet
  • Other: Ketogenic diet
    Ketogenic Diet breakfast, lunch, and dinner for 3 days.
    Other Names:
  • ~5-10% kcal carbohydrates diet
  • Outcome Measures

    Primary Outcome Measures

    1. Change in breath alcohol concentration [3 hours]

      Breath alcohol concertation measured in mg/210L of air. The range is .000 to .400 g/210L. Change in breath alcohol concentration, pre to post alcohol consumption after 3 day diet intervention during lab day.

    Secondary Outcome Measures

    1. Change in motor agility tasks [3 hours]

      Motor agility will be assessed with the grooved pegboard task, in which participants will place pegs onto a metal surface containing 25 keyhole-shaped holes that differ in orientation. Measured in seconds, range 0 to 5 minutes. Change in motor agility tasks pre to post alcohol consumption after 3 day diet intervention.

    2. Change in cognitive performance tasks [3 hours]

      Cognitive performance will be measured with a cued go/no-go task, in which participants will press a computer keyboard key in response to a "go" target and suppress the action in response to a "no-go" target. Measured in % correct responses 0-100. Pre to post alcohol consumption after 3 day diet intervention.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Willingness to provide signed, informed consent and commit to completing study procedures.

    2. Reported on at least one day in the month prior to consent of consuming 2 or more standard alcohol drinks on a single day.

    Exclusion Criteria:
    1. Unwilling or unable to refrain from use, within 24 hours of the alcohol lab procedures, psychoactive medications or medication that may affect study results.

    2. Current Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of any major psychiatric disorder (other than nicotine use disorders, or marijuana use disorders) as identified by clinical examination or structured interview that could interfere with study participation or make it hazardous for the subject.

    3. Currently taking medication(s) that could interfere with study participation or make it hazardous for the subject to participate. (e.g. anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified)

    4. Positive urine drug screen, positive for all substances but marijuana at screening or study visits (may be repeated once and if the result is negative on repeat, it is not exclusionary).

    5. A current, clinically significant physical disease or abnormality on the basis of medical history, or routine laboratory evaluation that can impact brain function, the use of a ketone supplement, administration of ketogenic diet, or the use of alcohol (e.g., epilepsy, diabetes, irritable bowel syndrome, Crohn's disease, liver disease, kidney disease, kidney stones, chronic metabolic acidosis or a cardiomyopathy as determined by history and clinical exam).

    6. Currently suffering from or has a history of stroke and/or stroke related spasticity.

    7. Head trauma with loss of consciousness for more than 30 minutes or associated with skull fracture, inter-cranial bleeding or abnormal MRI (self-report, medical history).

    8. Weight greater than 225lbs (Need to cap amount of alcohol given based on weight to individuals).

    9. Females who are pregnant or breast-feeding

    10. Contraindication to MRI, including presence of ferromagnetic objects, claustrophobia or fear of enclosed, medical conditions that prevent subjects from lying comfortably flat on his/ her back for up to 2 hrs.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Pennsylvania Center for Studies of Addiction Philadelphia Pennsylvania United States 19104

    Sponsors and Collaborators

    • University of Pennsylvania

    Investigators

    • Principal Investigator: Corinde Wiers, Ph.D., University of Pennsylvania
    • Study Director: Henry Kranzler, MD, University of Pennsylvania
    • Study Director: Kyle Kampman, MD, University of Pennsylvania

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Pennsylvania
    ClinicalTrials.gov Identifier:
    NCT06065657
    Other Study ID Numbers:
    • 853707
    • 24446
    First Posted:
    Oct 4, 2023
    Last Update Posted:
    Oct 4, 2023
    Last Verified:
    Sep 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University of Pennsylvania
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 4, 2023